Ariana Boswell

All articles by Ariana Boswell

• Age, left atrium size associated with atrial fibrillation in ATTR-CM

  In a recent study, left atrial dilation and advanced age were identified as predictors of atrial fibrillation in patients with ATTR-CM.

• Nex-Z receives Regenerative Medicine Advanced Therapy designation for ATTR-CM

  Nex-z, a CRISPR/Cas9 therapy, was found to promote sustained and prolonged reduction of transthyretin levels in patients with ATTR-CM.

• Biomarkers of worsening ATTR-CM identified in patients on tafamidis

  NT-proBNP levels and oral diuretic use were associated with cardiac disease worsening in patients with ATTR-CM taking tafamidis.

• Gene‑modulating therapies show promise in ATTR-CM

  A recent review article explores a variety of therapies being developed to target the root cause of ATTR-CM.

• FDA approves vutrisiran to treat ATTR-CM

  The FDA has approved vutrisiran (AMVUTTRA®) for the treatment of ATTR-CM based on favorable results from the HELIOS-B clinical trial.

• Webinar: Strategies for supporting mental health with ATTR-CM

  In a recent webinar, Meghan Beier, PhD, MA highlights several strategies for managing the emotional impacts of ATTR-CM.

• Case report: hATTR-CM in a patient with lung transplant complications

  A case report describes a 71-year old woman who was diagnosed with hereditary ATTR-CM after experiencing post-lung transplant complications.

• Raising awareness: Light the Night for Amyloidosis 2025

  In honor of March being Amyloidosis Awareness Month, the Amyloidosis Foundation is hosting its annual Light the Night campaign.

• Fully automated tool developed to detect and score ATTR-CM

  A new artificial intelligence-based tool may improve quick and accurate ATTR-CM diagnosis using scintigraphy images.

• SGLT2 inhibitors improve outcomes in ATTR-CM, study finds

  Sodium-glucose cotransporter 2 inhibitors may improve clinical outcomes and health care usage in patients with ATTR-CM.